Thomas Denton
Managing & Founding Director
Thomas founded Total Delivery Pharma in 2023 with a clear purpose: to bring precision, flexibility, and genuine patient focus to the pharmaceutical and medical device consultancy space.
With over a decade of experience spanning oral dosage forms, sterile manufacturing, medical devices, and cell and gene therapies, Thomas brings an unusually broad range of technical expertise to TDP’s clients. His career began in paramedicine and specialist aseptic services within the NHS before progressing into commercial and global roles across the pharmaceutical sector. This clinical foundation has shaped his patient-first approach and continues to drive his commitment to quality that delivers meaningful outcomes at the bedside.
Thomas leads TDP’s global team of experts and holds credentials as an ISO 9001 Lead Auditor and ISO 13485 Lead Auditor. He is also a pre-viva Trainee Qualified Person and an active Responsible Person and Responsible Person for Import.
Thomas has served on a Health Research Authority committee, contributing to the joint technical and ethical review of clinical trials involving pharmaceutical products and medical devices. His expertise across client engagements spans GMDP and GCP compliance, regulatory auditing, quality management system development, sterile manufacturing, and validation. He has supported organisations ranging from early-stage SMEs through to global multinational companies.
Thomas is particularly known for his ability to translate complex regulatory challenges into practical, durable solutions and for the forensic attention to detail he brings to every audit and project. He has a proven track record of establishing and operating licensed pharmaceutical businesses, including five Manufacturing and Importation Authorisations and two Wholesale Distribution Authorisations, as well as leading teams that influence and control critical business activities.
More recently, Thomas has expanded his work as a Board advisor and now leads a growing group of companies under the Total Delivery Group umbrella.
Selected achievements include:
Completing more than 100 audits across the GxP landscape
Participating in approval committees for more than 60 clinical trials involving pharmaceutical products and medical devices
Successfully remediating a global supplier quality and risk management system for a blue-chip pharmaceutical company
Completing the EPOCHA-RA-CH formulation stability trial for the NHS, supporting increased product shelf life and improved patient care
Building, delivering, executing, and operating five Manufacturing and Importation Authorisations and two Wholesale Distribution Authorisations
Managing 17 GMDP inspections across Canada, Belgium, France, the Netherlands, Australia, Switzerland, and the UK
What sets Thomas apart is not only the depth of his technical knowledge, but also the energy and creativity he brings to every challenge. He is a passionate advocate for digital and data-first working, continuous improvement, problem-solution thinking, and knowledge sharing.
Thomas leads TDP with the belief that the strongest outcomes come from combining technical rigour with genuine curiosity and patient centricity. Clients consistently describe working with TDP under his leadership as a privilege, and that is the standard he expects the wider team to uphold.
Latest Work
Learn how to diagnose pharmaceutical batch-review bottlenecks, protect QP capacity and recover backlogs without compromising compliance or supply.
Learn how to assess pharmaceutical technology-transfer readiness across CMC, MS&T, Quality and Regulatory before validation and commercial supply.
Learn how to build a risk-based pharmaceutical supplier qualification programme, identify hidden GxP risks and maintain effective ongoing supplier oversight.
A complete-looking data room isn't the same as a sound CMC and regulatory position. Learn what a genuine review checks, and the red flags that most often reprice or derail pharma deals.
A strong scientific story doesn't guarantee commercial success. Learn what a proper commercial viability analysis tests, and where pharma business case assumptions usually break.
Built for You or Built to Buy? The licensed entity model you choose shapes your QMS, staffing and documentation from day one. Learn how to decide before you build, not after
Batch release delays rarely start on the production floor. Learn why review capacity, not manufacturing, is usually the real constraint, and what a structured review model does differently.
A big market opportunity isn't the same as being ready to enter it. Learn what a proper market entry readiness assessment covers, from regulatory pathway to supply chain, before you commit a launch date.
A QMS that only works on paper isn't a QMS. Learn what separates a compliant-looking quality system from one your team can actually follow under real operational pressure.
Guidelines change constantly, and regulatory teams fall behind quietly, one missed update at a time. Learn what a structured currency programme looks like and how to build one without adding headcount.
Generic GMP training gets people through the module. It doesn't get them through an inspection. See what role-specific training does differently, and why it matters when regulators start asking questions.
EU GMP Annex 19 has been rewritten. If you handle parallel-traded product, Section 9 now sets prescriptive retention-sample rules and a new digital-sample option, effective 24 September 2026. Here's what changed, what it means for your SOPs, and how to run the gap assessment before the deadline.
Recognise the signs of a manufacturing capability gap before it hits your timeline or submission. TDP's MS&T consultants explain how to diagnose, address, and get ahead of the problem.
Expanding into new markets without a dedicated regulatory affairs team is the reality for many pharma companies. Here is how to build and manage a global submission programme that holds up under agency scrutiny — from pathway strategy and dossier architecture to post-submission management.
Scale-up failures don't just delay manufacturing. They delay regulatory approval. Learn how proactive MS&T input protects your programme and strengthens your CMC package.
Most regulatory submission delays trace back to CMC. Understand the most common gaps, why they happen, and how to prevent them before your filing reaches the agency.
Need specialist CMC expertise but cannot justify permanent headcount? Learn how outsourced CMC models give growing pharmaceutical companies the capability they need, at the stages they need it most.
Outsourcing regulatory affairs is not always the right call. But for many pharma businesses, it is. Here is how to know when the case stacks up
No quality team? No problem. Learn how scaling pharma companies build compliant, investor-ready quality functions without permanent headcount. Practical guidance from TDP.
No in-house audit team? Learn how to structure compliant GxP audit coverage using outsourced and retained models. Practical guidance for pharmaceutical and biotech organisations.
TDP's key takeaways from Making & Distributing Pharma 2026. What the MHRA said about AI governance, Annex 22, decentralised medicines, and the landmark transparency
Need a fast regulatory answer without starting a full project? TDP's Just Ask service gives you direct access to senior expertise within 24-48 hours. Find out how.
Received an inspection finding from the MHRA or FDA? Learn how to triage, structure a credible CAPA response, and protect your programme timeline. Expert guidance from TDP.
Total Delivery Pharma (TDP) announces a collaboration with Doc Check AI to explore AI-driven automation for GMP/GDP documentation and compliant document workflows.
Inside the TDP logo: a modern pharmacy “+”, an arterial droplet, and authoritative typography designed to signal GMP/GDP rigour and end-to-end delivery.
UK and EU healthcare regulations are diverging post-Brexit, requiring companies to navigate two evolving systems while maintaining compliance across both.
What GDP means in practice, why MHRA inspects it, where findings happen, and how to stay inspection-ready under a WDA(H).
Learn what a Responsible Person (RP) is, when you need one, what they do under GDP, how they differ from an RPi/QP, and how to appoint the right RP.
Learn what a Qualified Person (QP) does, when one is required, and how QP certification works under EU & UK GMP. Practical guidance from TDP.